Your Source for Venture Capital and Private Equity Financings

Elevian Raises $40M Series A

2021-09-17
ALLSTON, MA, Elevian, an emerging biotech company, has raised $40 million in an oversubscribed Series A round led by Prime Movers Lab.
Elevian, an emerging biotech company developing medicines that restore youthful regenerative capacity with the potential to treat and prevent multiple age-related diseases, has raised $40 million in an oversubscribed Series A round led by Prime Movers Lab.

Additional investors include Bold Capital, Leslie Ventures, John A Kuelbs Family Office and others.

Elevian is an emerging biotech company developing medicines that restore youthful regenerative capacity, with the potential to treat and prevent multiple age-related diseases. Elevian's scientific founders, working at the Harvard Department of Stem Cell and Regenerative Biology, discovered that treatment with the circulating factor GDF11 can regenerate the heart, brain, muscle and other tissues.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors


Featured Reading